[go: up one dir, main page]

TN2009000111A1 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use - Google Patents

Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Info

Publication number
TN2009000111A1
TN2009000111A1 TN2009000111A TN2009000111A TN2009000111A1 TN 2009000111 A1 TN2009000111 A1 TN 2009000111A1 TN 2009000111 A TN2009000111 A TN 2009000111A TN 2009000111 A TN2009000111 A TN 2009000111A TN 2009000111 A1 TN2009000111 A1 TN 2009000111A1
Authority
TN
Tunisia
Prior art keywords
compounds
methods
receptor antagonist
glucagon receptor
compositions containing
Prior art date
Application number
TN2009000111A
Other languages
English (en)
Inventor
John E Stelmach
Emma R Parmee
James R Tata
Keith G Rosauer
Ronald M Kim
Amy R Bittner
Jiang Chang
Christopher Joseph Sinz
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38982644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000111(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of TN2009000111A1 publication Critical patent/TN2009000111A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
TN2009000111A 2006-10-03 2009-03-31 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use TN2009000111A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896706P 2006-10-03 2006-10-03
PCT/US2007/020858 WO2008042223A1 (fr) 2006-10-03 2007-09-27 Composés antagonistes du récepteur du glucagon, compositions contenant de tels composés et procédés d'utilisation

Publications (1)

Publication Number Publication Date
TN2009000111A1 true TN2009000111A1 (en) 2010-08-19

Family

ID=38982644

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000111A TN2009000111A1 (en) 2006-10-03 2009-03-31 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Country Status (30)

Country Link
US (3) US20100004158A1 (fr)
EP (1) EP2079688B1 (fr)
JP (1) JP2010505828A (fr)
KR (1) KR20090076907A (fr)
CN (1) CN101535252A (fr)
AR (1) AR063022A1 (fr)
AU (1) AU2007305430B2 (fr)
BR (1) BRPI0717305A2 (fr)
CA (1) CA2664004C (fr)
CL (1) CL2007002841A1 (fr)
CO (1) CO6190512A2 (fr)
CR (1) CR10694A (fr)
DK (1) DK2079688T3 (fr)
EA (1) EA017800B1 (fr)
EC (1) ECSP099225A (fr)
ES (1) ES2390296T3 (fr)
GE (1) GEP20125506B (fr)
IL (1) IL197788A0 (fr)
MA (1) MA31963B1 (fr)
MX (1) MX2009003611A (fr)
NO (1) NO342172B1 (fr)
PE (1) PE20080676A1 (fr)
PL (1) PL2079688T3 (fr)
PT (1) PT2079688E (fr)
SI (1) SI2079688T1 (fr)
TN (1) TN2009000111A1 (fr)
TW (1) TW200821284A (fr)
UA (1) UA96308C2 (fr)
WO (1) WO2008042223A1 (fr)
ZA (1) ZA200901694B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1702919B1 (fr) * 2003-12-29 2012-05-30 Msd K.K. Nouveau derive de benzimidazole a substitution 2-heteroaryle
JP2009530381A (ja) * 2006-03-23 2009-08-27 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、この化合物を含む組成物及び使用方法
CA2650619A1 (fr) * 2006-05-16 2007-11-29 Merck And Co., Inc. Composes antagonistes du recepteur du glucagon, compositions contenant ces composes, et procedes d'utilisation
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8436043B2 (en) 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009140342A1 (fr) 2008-05-16 2009-11-19 Schering Corporation Antagonistes du récepteur de glucagon, compostions et procédé d'utilisation de ces composés
EP2326618B1 (fr) 2008-08-13 2014-10-15 Metabasis Therapeutics, Inc. Antagonistes de glucagon
US8436015B2 (en) * 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2738663A1 (fr) * 2008-10-03 2010-04-08 Schering Corporation Derives de spiro-imidazolone utilises en tant qu'antagonistes des recepteurs du glucagon
WO2010071750A1 (fr) * 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Composés antagonistes du récepteur du glucagon
US8697740B2 (en) 2009-01-12 2014-04-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011037815A1 (fr) 2009-09-22 2011-03-31 Schering Corporation Pyrrolidines inédites utilisées en tant qu'antagonistes des récepteurs au glucagon, compositions en contenant et leurs procédés d'utilisation
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
KR101506829B1 (ko) 2010-12-23 2015-03-30 화이자 인코포레이티드 글루카곤 수용체 조절제
HRP20161177T1 (hr) 2011-02-08 2016-11-04 Pfizer Inc. Modulator glukagonskog receptora
MX2014000855A (es) 2011-07-22 2014-04-30 Pfizer Moduladores receptores de glucagon de quinolinilo.
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
TW201427658A (zh) * 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP3154956A4 (fr) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Antagonistes du glucagon
CN107304180B (zh) * 2016-04-22 2022-04-29 浙江海正药业股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
CN109071420B (zh) * 2016-06-14 2021-06-18 上海昂睿医药技术有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
CN107759522B (zh) * 2016-08-15 2023-04-14 浙江海正药业股份有限公司 羧酸类衍生物、其制备方法及其在医药上的用途
MX385598B (es) 2016-08-30 2025-03-18 Regeneron Pharma Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.
WO2018075792A1 (fr) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Méthodes d'abaissement de niveaux de glycémie
WO2019040471A1 (fr) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Méthodes de traitement des troubles liés au cycle de l'urée par interférence avec la signalisation du récepteur du glucagon
EP3752249A1 (fr) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Antagonistes de récepteur de glucagon
CN112608378B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016442A1 (fr) 1995-10-31 1997-05-09 Merck & Co., Inc. Pyrroles de pyridyle substitues, compositions contenant de tels composes et mode d'utilisation
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
CA2271893A1 (fr) 1996-11-20 1998-05-28 Linda L. Chang Imidazoles substitues au triaryl comme antagonistes du glucagon
AU726311B2 (en) 1996-11-20 2000-11-02 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
EP0948257A4 (fr) 1996-11-20 1999-12-29 Merck & Co Inc Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
ATE389636T1 (de) 1997-12-19 2008-04-15 Amgen Inc Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
PL352367A1 (en) 1999-05-17 2003-08-25 Novo Nordisk As Glucagon antagonists/inverse agonists
KR20030029061A (ko) 2000-06-23 2003-04-11 노보 노르디스크 에이/에스 글루카곤 길항제/역작용제
WO2002040444A1 (fr) 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
MXPA03009000A (es) * 2001-04-13 2004-02-12 Boehringer Ingelheim Pharma Compuestos benzo-fusionados 1,4-disustituidos.
PL370361A1 (en) * 2001-09-18 2005-05-16 F.Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
AU2002365622A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
WO2003051357A1 (fr) 2001-12-19 2003-06-26 Novo Nordisk A/S Antagonistes/agonistes inverses du recepteur du glucagon
WO2003053938A1 (fr) 2001-12-20 2003-07-03 Novo Nordisk A/S Nouveaux antagonistes/agonistes inverses du recepteur du glucagon
US7514452B2 (en) 2002-02-01 2009-04-07 Dainippon Pharmaceutical Co., Ltd 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
WO2004002480A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Nouveaux antagonistes/agonistes inverses du glucagon
HRP20050181A2 (en) * 2002-08-29 2006-03-31 Merck & Co. Inc. Indoles having anti-diabetic activity
JP2008533200A (ja) * 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
CN101535252A (zh) 2009-09-16
GEP20125506B (en) 2012-04-25
EA200970342A1 (ru) 2009-10-30
CA2664004A1 (fr) 2008-04-10
US7687534B2 (en) 2010-03-30
SI2079688T1 (sl) 2012-12-31
MX2009003611A (es) 2009-04-22
ES2390296T3 (es) 2012-11-08
ECSP099225A (es) 2009-07-31
US20080085926A1 (en) 2008-04-10
WO2008042223A1 (fr) 2008-04-10
EP2079688A1 (fr) 2009-07-22
PT2079688E (pt) 2012-11-22
US7968589B2 (en) 2011-06-28
NO20091734L (no) 2009-06-04
CA2664004C (fr) 2013-07-23
PE20080676A1 (es) 2008-06-12
AU2007305430B2 (en) 2011-07-21
KR20090076907A (ko) 2009-07-13
US20100004158A1 (en) 2010-01-07
AR063022A1 (es) 2008-12-23
MA31963B1 (fr) 2011-01-03
US20100144824A1 (en) 2010-06-10
ZA200901694B (en) 2010-01-27
IL197788A0 (en) 2009-12-24
PL2079688T3 (pl) 2013-01-31
CL2007002841A1 (es) 2008-02-08
JP2010505828A (ja) 2010-02-25
TW200821284A (en) 2008-05-16
CR10694A (es) 2009-05-25
EP2079688B1 (fr) 2012-07-25
BRPI0717305A2 (pt) 2014-03-25
DK2079688T3 (da) 2012-11-05
AU2007305430A1 (en) 2008-04-10
EA017800B1 (ru) 2013-03-29
UA96308C2 (ru) 2011-10-25
NO342172B1 (no) 2018-04-09
CO6190512A2 (es) 2010-08-19

Similar Documents

Publication Publication Date Title
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007111864A3 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
WO2006104826A3 (fr) Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation
WO2008076243A3 (fr) Composés acyl-bipipéridinyle, compositions contenant de tels composés et procédés de traitement
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
EP1773330A4 (fr) Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
EP1590336A4 (fr) Pyrazoles substitues, compositions contenant de tels composes et procedes d'utilisation
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
GEP20074197B (en) 5ht2c receptor modulators
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
EP1874301A4 (fr) Agonistes du recepteur de la niacine, compositions les contenant et methodes de traitement
IL188329A0 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
TW200800967A (en) Benzimidazole thiophene compounds
WO2008013987A3 (fr) Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
JO2645B1 (en) Vehicles
UA96277C2 (en) Benzimidazole derivatives
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
GB0611907D0 (en) Compounds
EP1971602A4 (fr) Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden